Athenex has run out of road. With programs stumbling and cash running out, the drug developer has filed for bankruptcy and begun seeking buyers for its three businesses.
May 14 (Reuters) - Drugmaker Athenex Inc (ATNX.O) and certain of its subsidiaries voluntarily filed for Chapter 11 proceedings, the company said on Sunday.
TONAWANDA, N.Y., May 3, 2023 /PRNewswire/ -- Pine Pharmaceuticals, one of the nation's largest and most trusted FDA-registered 503B outsourcing facilities, today announced the successful integration of Athenex's 503B business, including the transfer of people, processes, and products. The move has allowed Pine Pharmaceuticals to expand its product offerings, including critical, life-saving medications such as phenylephrine, epinephrine, vasopressin, and diltiazem injections.
Athenex is in a tight spot, trying to stretch out its remaining cash and ward off an unruly creditor just as the FDA slaps a clinical hold on its neuroblastoma cell therapy while it explores a patient's death in a phase 1 trial.
Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update
Athenex Announces a Reverse Stock Split
The New York-based cancer biotech Athenex has faced some struggles over the past year, but the company is moving to shutter the doors of one of its manufacturing sites.
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
Athenex Exits 503B Sterile Compounding Business
Shareholders voted in favor of all three proposals submitted before the Special Stockholder Meeting BUFFALO, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global...